Guide
Mazdutide vs survodutide vs retatrutide
Three peptides that add the glucagon receptor to GLP-1. Which receptors each one hits, who developed it, and how they sit next to semaglutide and tirzepatide.
Published September 23, 2026
Mazdutide and survodutide activate two receptors, GLP-1 and glucagon. Retatrutide activates those two plus a third, GIP. All three belong to the newer group of incretin peptides that add glucagon receptor activity to the GLP-1 signal semaglutide is known for.
| Peptide | Vial sizes | From |
|---|---|---|
| Mazdutide | 10mg | $109.99 CAD |
| Survodutide | 10mg | $119.99 CAD |
| Retatrutide | 5mg, 10mg, 20mg, 30mg, 40mg, 50mg, 60mg | $53.99 CAD |
Free shipping across Canada. Every vial ships with a QR code linking to its own batch lab report. See all peptides
Which receptors each one hits
| Peptide | GLP-1 | GIP | Glucagon | Developer |
|---|---|---|---|---|
| Semaglutide | Yes | Novo Nordisk | ||
| Tirzepatide | Yes | Yes | Eli Lilly | |
| Mazdutide | Yes | Yes | Innovent Biologics (licensed from Eli Lilly) | |
| Survodutide | Yes | Yes | Boehringer Ingelheim, with Zealand Pharma | |
| Retatrutide | Yes | Yes | Yes | Eli Lilly |
Read down the glucagon column and the split is clear. Semaglutide and tirzepatide leave the glucagon receptor alone. Mazdutide, survodutide and retatrutide all include it. Semaglutide vs tirzepatide vs retatrutide covers the first half of the table in more depth.
Why add glucagon to GLP-1
Glucagon and GLP-1 pull blood glucose in opposite directions. In research models, glucagon receptor activity raises energy expenditure and fat oxidation in the liver, but on its own it also raises glucose. GLP-1 receptor activity lowers glucose. A peptide that does both is designed to keep the energy-expenditure side of glucagon while GLP-1 offsets its effect on glucose.
That design goal is the reason all three of these molecules exist. Where they differ is in how the two (or three) receptor signals are balanced, which each developer tuned separately.
Mazdutide
Mazdutide is modeled on oxyntomodulin, a natural gut hormone that already activates both the GLP-1 and glucagon receptors. It carries two development codes: LY3305677 from Eli Lilly, where it started, and IBI362 from Innovent Biologics, which developed it under licence. It is studied in metabolic and energy-balance research. We sell mazdutide in a 10 mg vial.
Survodutide
Survodutide, development code BI 456906, is a GLP-1 and glucagon dual agonist from Boehringer Ingelheim, developed with Zealand Pharma. Alongside metabolic research, it has been studied in liver-fat models, which fits the hepatic side of glucagon receptor activity. We sell survodutide in a 10 mg vial.
Retatrutide
Retatrutide, Eli Lilly's LY3437943, is the triple agonist of the three: GLP-1, GIP and glucagon. Its molecular weight is 4731.32 g/mol (formula C221H342N46O68, CAS 2381089-83-2). We sell it in seven vial sizes, from 5 mg to 60 mg. The retatrutide handling guide has its concentration table, and retatrutide in Canada covers what is legal to sell here.
Identifiers we publish, and the ones we do not yet
Retatrutide's formula, mass and CAS number are printed on its product page. For mazdutide and survodutide we have not printed a formula or CAS number yet. Published reference values for newer peptides are sometimes inconsistent, and we would rather print nothing than print a wrong number that looks authoritative. Every vial's own lab report still states the observed mass for its batch, and the QR code on the vial opens that report.
Where the amylin peptides fit
Cagrilintide and eloralintide sit in the same part of the catalog but act on a different receptor family entirely: amylin, not GLP-1, GIP or glucagon. Cagrilintide vs semaglutide explains that difference.
Every vial from pepuro ships free, from our Calgary, Toronto and Vancouver distribution centers, the same business day your e-Transfer clears, with a QR code on the vial that opens its independent, third-party lab report.
For research use only. Not for human or animal consumption.
Frequently asked questions
What is the difference between mazdutide and survodutide?
+
They target the same two receptors, GLP-1 and glucagon, but they are different molecules from different developers. Mazdutide (IBI362, LY3305677) is an oxyntomodulin-based peptide developed by Innovent Biologics under licence from Eli Lilly. Survodutide (BI 456906) comes from Boehringer Ingelheim with Zealand Pharma.
How is retatrutide different from both?
+
Retatrutide adds a third receptor, GIP. It activates GLP-1, GIP and glucagon receptors, where mazdutide and survodutide activate GLP-1 and glucagon only.
Why add the glucagon receptor at all?
+
In research models, glucagon receptor activity raises energy expenditure and fat oxidation in the liver. Pairing it with GLP-1 activity, which lowers glucose, is meant to keep glucagon's glucose-raising effect in check. That combination is what these molecules are built to study.
Is mazdutide the same as IBI362?
+
Yes. IBI362 is Innovent's development code for mazdutide, and LY3305677 is the code it carried at Eli Lilly.
Related articles
- CJC-1295 and ipamorelin: why they are pairedA GHRH analog and a ghrelin agonist in one vial. Why the two are studied together, what each half does, and the molar concentrations once reconstituted.
- DSIP (delta sleep-inducing peptide) handling guideDSIP's numbers in one place: the nine-residue sequence, mass, where the name came from, vial sizes, concentration table and what its report should show.
- Gonadorelin peptide: handling, salt forms and GnRH pulsingGonadorelin is synthetic GnRH, the ten-residue native sequence. Mass, salt forms, why pulsing matters in research, concentration and what its report shows.
Ready to source from Canada's most transparent peptide store?
Browse peptides